End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.38 CNY | +1.65% | +3.31% | -23.27% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With a 2024 P/E ratio at 34.38 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.27% | 26Cr | - | ||
+5.32% | 4.06TCr | B- | ||
-21.04% | 2.18TCr | B- | ||
-16.29% | 1.31TCr | B- | ||
-13.00% | 983.61Cr | B+ | ||
+20.46% | 836.94Cr | C+ | ||
+7.95% | 673.48Cr | C+ | ||
-30.48% | 527.6Cr | C | ||
-24.80% | 358.54Cr | B+ | ||
-21.48% | 343.03Cr | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301237 Stock
- Ratings Hangzhou Heshun Technology Co.,LTD.